ClinicalTrials.gg

How we know

Every link on this study, and who decided it

The study on the left, the conditions and drugs this site links it to, and on each link the judgments that made or checked it, by day and by judge. The top row is the record itself: each new version seen since tracking began. Dashed lines are links the registry record does not make itself. Select a link to see everything judged on it, or a mark for one decision with its reason and evidence.

11 links0 made here, not in the record22 judgments2 judges (the rules as one: Rule based)1 record change seen
Claude Opus 5.5Rule basedRecord updated on ClinicalTrials.gov
Oct 19Oct 26Nov 2Nov 9Nov 16TodayNCT02794571Safety and Pharmacokinetics(PK) of Escalating Doses ofTiragolumab as a SingleAgent and in CombinationWith Atezolizumab and/orOther Anti-Cancer Therapiesin Locally Advanced orGenentech, Inc.Phase 1 · completedRECORDThe record itselfVersions seen nightly since Sep 25, 2…›Nov 8 · ClinicalTrials.gov record · MeSH filing re-derivedMeSH filing re-derivedCONDITIONSNeoplasm MetastasisThe registry's MeSH filing›Nov 14 · Rule based · General: a category, not a diseaseAs of now · Rule based · Main conditionMain conditionDRUGSAtezolizumabIntervention entry›Nov 3 · Claude Opus 5.5 · Background · partnerNov 18 · Rule based · TestedBackground · partnerTiragolumabIntervention entry›Nov 3 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedCarboplatinIntervention entry›Nov 3 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundCisplatinIntervention entry›Nov 3 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundPemetrexedIntervention entry›Nov 3 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundPaclitaxelIntervention entry›Nov 3 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundEtoposideIntervention entry›Nov 3 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundCapecitabineIntervention entry›Nov 3 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundBevacizumabIntervention entry›Nov 3 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundPembrolizumabIntervention entry›Nov 3 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackground

Times are in your time zone; a day marked “day only” kept no time. The graph scrolls sideways on a narrow screen; every mark is also in the list below.

Atezolizumab

From the registry record2 judgments on this link
Role in the study, from the registry to what was judged
RegistryEntry “Atezolizumab”the record gives no role
→judged→changed
How the 2 judgments split50%of judgments with a known value say Background · partner
Background · partner · 1
Tested · 1

All judgments on this study

WhenLinkJudgeDecisionState
Nov 3AtezolizumabClaude Opus 5.5Background · partnerCurrent
Nov 3TiragolumabClaude Opus 5.5TestedCurrent
Nov 3CarboplatinClaude Opus 5.5BackgroundCurrent
Nov 3CisplatinClaude Opus 5.5BackgroundCurrent
Nov 3PemetrexedClaude Opus 5.5BackgroundCurrent
Nov 3PaclitaxelClaude Opus 5.5BackgroundCurrent
Nov 3EtoposideClaude Opus 5.5BackgroundCurrent
Nov 3CapecitabineClaude Opus 5.5BackgroundCurrent
Nov 3BevacizumabClaude Opus 5.5BackgroundCurrent
Nov 3PembrolizumabClaude Opus 5.5BackgroundCurrent
Nov 8The record itselfClinicalTrials.gov recordMeSH filing re-derivedRecord change
Nov 14Neoplasm MetastasisRule based · condition-kind ruleGeneral: a category, not a diseaseCurrent
Nov 18AtezolizumabRule based · role ruleTestedOverridden
Nov 18TiragolumabRule based · role ruleTestedAgrees
Nov 18CarboplatinRule based · role ruleBackgroundAgrees
Nov 18CisplatinRule based · role ruleBackgroundAgrees
Nov 18PemetrexedRule based · role ruleBackgroundAgrees
Nov 18PaclitaxelRule based · role ruleBackgroundAgrees
Nov 18EtoposideRule based · role ruleBackgroundAgrees
Nov 18CapecitabineRule based · role ruleBackgroundAgrees
Nov 18BevacizumabRule based · role ruleBackgroundAgrees
Nov 18PembrolizumabRule based · role ruleBackgroundAgrees
As of nowNeoplasm MetastasisRule based · main-condition ruleMain conditionCurrent

The rules, in plain words

“Rule based” means one of these decided, not a model or a person. Each runs every night over every study.

Which drugs a study tests

Reads each treatment the study lists and the arms it is in. A drug only in the experimental arm is tested. A drug in every arm while something else changes between the arms is given beside it. A drug only in the control arm is the comparator. Placebo, procedures and usual care are known by name.

Where the whole record has been read, that reading's answer replaces the rule's.

What a study is mainly about

Starts from the first condition ClinicalTrials.gov files the study under. It moves to a narrower one only when the study's own title or listed conditions name it, and sets aside terms the registry often files by mistake. A study open to many cancers is not placed under one of them unless its title names it.

Checked against studies judged one by one; the study page says when it differs from the registry.

How a condition link is counted

For each condition a study is filed under: whether it is the study's own condition at the finest the study states it, a wider one, a general category, or filed by mistake; and whether it is the main condition, a setting the study names, or only how it was filed.

A decision on file for one study overrides it, with who made it and when.